Mundipharma EDO and Imbrium Therapeutics announced that the FDA granted orphan drug designation to etoposide toniribate for the treatment of cholangiocarcinoma, according to a press release.
“We are pleased that the FDA has recognized etoposide toniribate as a potential treatment for relapsed/refractory biliary tract cancer,” Thomas Mehrling, MD, PhD, CEO of Mundipharma EDO, said in the release. “As a company we are focused on developing treatments for rare and difficult-to-treat cancers and getting them to patients as rapidly as possible. We look forward to accelerating the

Source link